Hematologic Disease
Phase I study of 506U78 for refractory hematologic malignancies conducted
Published in Cancer Weekly, July 26th, 2005
According to recent research from the United States, "A phase I study was conducted to determine the maximum-tolerated dose (MTD), toxicity profile, and pharmacokinetics of a novel purine nucleoside, nelarabine, a soluble prodrug of 9-beta-D-arabinosylguanine (araG; Nelarabine), in pediatric and adult patients with refractory hematologic malignancies. Between April 1994 and April 1997, 93 patients with refractory hematologic malignancies were treated with 1 to 16 cycles of study drug."
"Nelarabine was administered...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-07-26)
More Articles from Cancer Weekly
- Cancer Risk Factors
Associated nutritional risk of breast and colon cancers disproved - Cancer Survival
Personality not associated with cancer survival - Lung Cancer
NAT2 genotype associated with increased risk of lung cancer among never-smokers - Mental Illness
Adolescents' perception of stigma of mental illness and alcohol abuse reviewed - Adenovirus
Adenovirus examined, E1B-AP5 interaction with p53 reported - Advocacy
Lung cancer nonprofit program launches newly redesigned Internet site - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
